Liu, Chen-Hua
Huang, Chung-Feng
Liu, Chun-Jen
Dai, Chia-Yen
Huang, Jee-Fu
Lin, Jou-Wei
Liang, Cheng-Chao
Yang, Sheng-Shun
Lin, Chih-Lin
Su, Tung-Hung
Yang, Hung-Chih
Chen, Pei-Jer
Chen, Ding-Shinn
Chuang, Wan-Long
Kao, Jia-Horng
Yu, Ming-Lung
Article History
Received: 23 March 2015
Accepted: 1 June 2015
First Online: 1 July 2015
Competing interests
: Chen-Hua Liu: consultant for Abbott, Abbvie, Bristol-Myers Squibb, Roche; on speaker’s bureau for Abbott, Roche, Bristol-Myer Squibb, GlaxoSmithKline, Novartis. Jia-Horng Kao: consultant for Abbott, Abbvie, Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline, Merck Sharp & Dohme, Novartis, Roche; on speaker’s bureau for Abbott, Abbvie, Roche, Bayer, Bristol-Myers Squibb, GlaxoSmithKline, Novartis; Ding-Shinn Chen: consultant for Novartis and GlaxoSmithKline; Pei-Jer Chen: consultant for Novartis and Roche; Ming-Lung Yu and Wan-Long Chuang: consultants for Merck Sharp & Dohme Abbott and Abbvie; grants support from Abbott and Roche; on speaker’s bureau from Bristol-Myers Squibb, Roche, Merck Sharp & Dohme, GlaxoSmithKline, Novartis and Gilead Sciences. All other authors declare no competing interests.